Dr. Klopp on a Comparison of Standard Radiation to IMRT in Gynecologic Malignancies

Video

In Partnership With:

Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center, discusses the results of a study that compared the respective toxicities and quality of life outcomes associated with standard radiation and pelvic intensity-modulated radiation therapy for patients with various gynecologic malignancies.

Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center, discusses the results of a study that compared the respective toxicities and quality of life outcomes associated with standard radiation and pelvic intensity-modulated radiation therapy (IMRT) for patients with various gynecologic malignancies.

The overall goal of this study was to look at acute toxicities that occurred during the course of a patient's treatment with the use of the bowel domain of the expanded prostate cancer index composite (EPIC) questionnaire, which evaluated patient bowel function and bowel bother.

According to Klopp, the researchers found that there was a greater decline in gastrointestinal function in patients that received standard radiation, whereas the patients who received experienced less of a decline. Moreover, this was also associated with improved quality of life.

Remaining questions regarding this research should focus on whether these differences in technique are persistent in a long-term sense, says Klopp.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology